PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
ProPhase Labs statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Market Cap | $133.15K | $164.85M |
| Enterprise Value | $113.15K | $87.06M |
| PS Ratio | 0.03 | 3.60 |
Enterprise value
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| EV / Sales | 0.03 | 2.43 |
Income (trailing twelve months)
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Revenue | $3.85M | $57.94M |
| Gross Profit | $645.00K | $90.47M |
| Operating Income | -$15.56M | -$21.44M |
| Pretax Income | -$21.86M | -$14.45M |
| Net Income | -$22.46M | -$22.46M |
| EBITDA | -$12.32M | -$16.91M |
Margins
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Gross Margin | 16.8% | 52.3% |
| Operating Margin | -404.5% | -44.5% |
| Pretax Margin | -568.1% | -13.0% |
| Profit Margin | -583.9% | -39.2% |
| EBITDA Margin | -320.1% | -31.3% |
Returns
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Return on Equity (ROE) | -539.7% | -53.1% |
| Return on Assets (ROA) | -45.2% | -41.0% |
| Return on Invested Capital (ROIC) | -302.3% | -32.0% |
Growth
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -31.2% | 6.01% |
| Revenue Growth (3Y CAGR) | -67.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -21.4% | 6.42% |
Balance sheet
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $20.00K | $62.42M |
| Net Cash (Debt) | $20.00K | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$3.11M | $48.79M |
| Book Value Per Share | -$0.20 | $1.36 |
| Tangible Book Value | -$12.96M | $23.06M |
| Working Capital | -$55.29M | $75.77M |
Financial position
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Current Ratio | 0.05 | 3.30 |
| Quick Ratio | 0.03 | 2.39 |
| Interest Coverage | -2.15 | -7.12 |
Cash flow (trailing twelve months)
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.54M | -$12.35M |
Efficiency
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Inventory Turnover | 7.12 | 2.67 |
| Revenue Per Employee | $202.47K | $398.96K |
| Profits Per Employee | -$1.18M | -$703.34K |
| Employee Count | 19 | 74 |
Dividends and yields
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Earnings Yield | -16871.1% | -22.7% |
| Buyback Yield | -30.8% | -0.73% |
| Shareholder Yield | -30.8% | 0.00% |
Shares
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Shares Outstanding | 15,592,600 | 58,179,650 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 11,735,000 | 49,173,100 |
| Shares Held by Insiders | 24.7% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Income Tax | $607.00K | $91.50K |
Scores
| Measure | ProPhase Labs | Industry median |
|---|---|---|
| Altman Z-Score | -3.97 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from ProPhase Labs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.